In vivo monitoring of oxidative protein folding through time-resolved quantitative mass spectrometry

通过时间分辨定量质谱法体内监测氧化蛋白折叠

基本信息

  • 批准号:
    9167306
  • 负责人:
  • 金额:
    $ 189万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-09-30 至 2021-08-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Despite decades of study, how proteins fold in cells remains poorly understood. Protein folding and misfolding underlies the pathogenesis of diseases ranging from cancer to neurodegeneration. Much of what we do know about protein folding has been gathered from in vitro experiments, which do not fully model the complex intracellular environment including chaperones, membranes, and other biomolecules. Furthermore, our current knowledge of folding, both in vitro and in vivo, primarily relies on low-throughput, single-protein experiments. While providing great detail, these methods cannot simultaneously test how differential folding and misfolding across the proteome impacts disease physiology. Over 20% of human proteins contain disulfide bonds, and formation of these bonds typically represents the rate-limiting step in achieving the native fold under oxidizing conditions. Therefore, monitoring the kinetics of native disulfide bond formation can provide a proxy for successful protein folding (Mamathambika and Bardwell, 2008). Our group has pioneered the use of targeted mass spectrometry to monitor cellular protein synthesis. Here, we propose an entirely new approach to monitor oxidative protein folding across hundreds of proteins simultaneously: using targeted, quantitative mass spectrometry to monitor the kinetics of native disulfide bond formation in vivo. In my group we specifically focus on the study of multiple myeloma, a hematologic malignancy of plasma cells with no known cure. This disease is fundamentally a disorder of aberrant protein homeostasis: it is thought that unregulated production of immunoglobulin leads to many of the known clinical sequelae, while inducing apoptosis by increasing unfolded protein stress is a first-line therapeutic strategy. Here, we will first develop biochemical and proteomic tools to monitor native disulfide bond formation in nascently synthesized proteins within the endoplasmic reticulum. We will then use these tools, in combination with tuning of immunoglobulin protein synthesis through CRISPR inhibition and activation, to test the clinically-relevant hypothesis that myeloma cells are exquisitely sensitive to proteasome inhibition due to increased unfolded protein stress. Finally, we will test the effects of modulation of oxidative folding chaperones on simultaneous folding kinetics across many classes of myeloma-relevant secreted and extracellular proteins. We anticipate that these experimental approaches will provide a significant advance toward our understanding of global protein folding in vivo, thereby addressing a major gap in our knowledge of this central biological process. Furthermore, our results here will provide a breakthrough toward the study of a broad range of intracellular protein dynamics that are inaccessible with other methods.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Arun P. Wiita其他文献

Cellular immunotherapy targeting CLL-1 for juvenile myelomonocytic leukemia
针对 CLL-1 的细胞免疫疗法用于幼年型粒单核细胞白血病
  • DOI:
    10.1038/s41467-025-59040-6
  • 发表时间:
    2025-04-23
  • 期刊:
  • 影响因子:
    15.700
  • 作者:
    Juwita Werner;Alex G. Lee;Chujing Zhang;Sydney Abelson;Sherin Xirenayi;Jose Rivera;Khadija Yousuf;Hanna Shin;Bonell Patiño-Escobar;Stefanie Bachl;Kamal Mandal;Abhilash Barpanda;Emilio Ramos;Adila Izgutdina;Sibapriya Chaudhuri;William C. Temple;Shubhmita Bhatnagar;Jackson K. Dardis;Julia Meyer;Carolina Morales;Soheil Meshinchi;Mignon L. Loh;Benjamin Braun;Sarah K. Tasian;Arun P. Wiita;Elliot Stieglitz
  • 通讯作者:
    Elliot Stieglitz
Bladder cancer variants share aggressive features including a CA125+ cell state and targetable TM4SF1 expression
膀胱癌变异体具有侵袭性特征,包括 CA125+细胞状态和可靶向的 TM4SF1 表达
  • DOI:
    10.1038/s41467-025-59888-8
  • 发表时间:
    2025-06-17
  • 期刊:
  • 影响因子:
    15.700
  • 作者:
    Heiko Yang;Hanbing Song;Elizabeth Yip;Timothy Gilpatrick;Kevin Chang;Paul Allegakoen;Kevin L. Lu;Keliana Hui;Julia H. Pham;Corynn Kasap;Vipul Kumar;Janae Gayle;Bradley A. Stohr;Chien-Kuang Cornelia Ding;Arun P. Wiita;Maxwell V. Meng;Jonathan Chou;Sima P. Porten;Franklin W. Huang
  • 通讯作者:
    Franklin W. Huang
Time-resolved proteomics vs. ribosome profiling reveals translation dynamics under stress
时间分辨蛋白质组学与核糖体分析揭示了压力下的翻译动态
  • DOI:
    10.1101/087486
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Tzu;Hector H. Huang;Diamond Wheeler;James A. Wells;Yun S. Song;Arun P. Wiita
  • 通讯作者:
    Arun P. Wiita
Tumour-wide RNA splicing aberrations generate actionable public neoantigens
肿瘤范围的 RNA 剪接异常产生可操作的公共新抗原
  • DOI:
    10.1038/s41586-024-08552-0
  • 发表时间:
    2025-02-19
  • 期刊:
  • 影响因子:
    48.500
  • 作者:
    Darwin W. Kwok;Nicholas O. Stevers;Iñaki Etxeberria;Takahide Nejo;Maggie Colton Cove;Lee H. Chen;Jangham Jung;Kaori Okada;Senthilnath Lakshmanachetty;Marco Gallus;Abhilash Barpanda;Chibo Hong;Gary K. L. Chan;Jerry Liu;Samuel H. Wu;Emilio Ramos;Akane Yamamichi;Payal B. Watchmaker;Hirokazu Ogino;Atsuro Saijo;Aidan Du;Nadia R. Grishanina;James Woo;Aaron Diaz;Shawn L. Hervey-Jumper;Susan M. Chang;Joanna J. Phillips;Arun P. Wiita;Christopher A. Klebanoff;Joseph F. Costello;Hideho Okada
  • 通讯作者:
    Hideho Okada
DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma
DNA 甲基转移酶抑制剂上调多发性骨髓瘤中 CD38 蛋白表达并增强达雷木单抗疗效
  • DOI:
    10.1038/s41375-019-0587-5
  • 发表时间:
    2019-10-08
  • 期刊:
  • 影响因子:
    13.400
  • 作者:
    Priya Choudhry;Margarette C. Mariano;Huimin Geng;Thomas G. Martin;Jeffrey L. Wolf;Sandy W. Wong;Nina Shah;Arun P. Wiita
  • 通讯作者:
    Arun P. Wiita

Arun P. Wiita的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Arun P. Wiita', 18)}}的其他基金

Structural Surfaceomics: A Strategy for Immunotherapy Target Discovery
结构表面组学:免疫治疗靶点发现的策略
  • 批准号:
    10290239
  • 财政年份:
    2021
  • 资助金额:
    $ 189万
  • 项目类别:
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy
利用骨髓瘤蛋白质组重塑来延长蛋白酶体抑制剂的功效
  • 批准号:
    10308238
  • 财政年份:
    2021
  • 资助金额:
    $ 189万
  • 项目类别:
ClinTAD: A Tool for Improving Clinical CNV Interpretation
ClinTAD:改善临床 CNV 解读的工具
  • 批准号:
    10461112
  • 财政年份:
    2021
  • 资助金额:
    $ 189万
  • 项目类别:
Structural Surfaceomics: A Strategy for Immunotherapy Target Discovery
结构表面组学:免疫治疗靶点发现的策略
  • 批准号:
    10434121
  • 财政年份:
    2021
  • 资助金额:
    $ 189万
  • 项目类别:
ClinTAD: A Tool for Improving Clinical CNV Interpretation
ClinTAD:改善临床 CNV 解读的工具
  • 批准号:
    10286951
  • 财政年份:
    2021
  • 资助金额:
    $ 189万
  • 项目类别:
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy
利用骨髓瘤蛋白质组重塑来延长蛋白酶体抑制剂的功效
  • 批准号:
    10341162
  • 财政年份:
    2018
  • 资助金额:
    $ 189万
  • 项目类别:
Exploiting myeloma proteome remodeling to extend proteasome inhibitor efficacy
利用骨髓瘤蛋白质组重塑来延长蛋白酶体抑制剂的功效
  • 批准号:
    10524110
  • 财政年份:
    2018
  • 资助金额:
    $ 189万
  • 项目类别:
Global Assessment of Myeloma Response to Chemotherapy
骨髓瘤化疗反应的整体评估
  • 批准号:
    8819976
  • 财政年份:
    2014
  • 资助金额:
    $ 189万
  • 项目类别:
Global Assessment of Myeloma Response to Chemotherapy
骨髓瘤化疗反应的整体评估
  • 批准号:
    8928081
  • 财政年份:
    2014
  • 资助金额:
    $ 189万
  • 项目类别:
Global Assessment of Myeloma Response to Chemotherapy
骨髓瘤化疗反应的整体评估
  • 批准号:
    9337420
  • 财政年份:
    2014
  • 资助金额:
    $ 189万
  • 项目类别:

相似国自然基金

Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 批准年份:
    2020
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 批准年份:
    2017
  • 资助金额:
    20.0 万元
  • 项目类别:
    青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 批准年份:
    2016
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 批准年份:
    2014
  • 资助金额:
    73.0 万元
  • 项目类别:
    面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
  • 批准号:
    81301123
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
  • 批准号:
    81101529
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
  • 批准号:
    39500043
  • 批准年份:
    1995
  • 资助金额:
    9.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Optogenetic and Biochemical Studies of Novel Roles of beta-Catenin Modulation/Addiction in Neuronal Differentiation and Apoptosis
β-连环蛋白调节/成瘾在神经元分化和细胞凋亡中新作用的光遗传学和生化研究
  • 批准号:
    8984020
  • 财政年份:
    2015
  • 资助金额:
    $ 189万
  • 项目类别:
Proteomic and Biochemical Studies of Bax Regulatory Proteins in Apoptosis
Bax 细胞凋亡调节蛋白的蛋白质组学和生化研究
  • 批准号:
    8051912
  • 财政年份:
    2010
  • 资助金额:
    $ 189万
  • 项目类别:
Structural/Biochemical Analysis: Apoptosis in C. elegans
结构/生化分析:线虫细胞凋亡
  • 批准号:
    7175363
  • 财政年份:
    2005
  • 资助金额:
    $ 189万
  • 项目类别:
Biochemical and structural characterisation of key protein interactions during apoptosis
细胞凋亡过程中关键蛋白质相互作用的生化和结构表征
  • 批准号:
    nhmrc : 356255
  • 财政年份:
    2005
  • 资助金额:
    $ 189万
  • 项目类别:
    Career Development Fellowships
Structural/Biochemical Analysis: Apoptosis in C. elegans
结构/生化分析:线虫细胞凋亡
  • 批准号:
    6850982
  • 财政年份:
    2005
  • 资助金额:
    $ 189万
  • 项目类别:
Structural/Biochemical Analysis: Apoptosis in C. elegans
结构/生化分析:线虫细胞凋亡
  • 批准号:
    7345488
  • 财政年份:
    2005
  • 资助金额:
    $ 189万
  • 项目类别:
Structural/Biochemical Analysis: Apoptosis in C. elegans
结构/生化分析:线虫细胞凋亡
  • 批准号:
    7011254
  • 财政年份:
    2005
  • 资助金额:
    $ 189万
  • 项目类别:
MITOCHONDRIA, OXIDATIVE STRESS AND NEURONAL APOPTOSIS: BIOCHEMICAL, CELLULAR AND PHARMACOLOGICAL APPROACHES
线粒体、氧化应激和神经元凋亡:生物化学、细胞和药理学方法
  • 批准号:
    nhmrc : 194323
  • 财政年份:
    2002
  • 资助金额:
    $ 189万
  • 项目类别:
    NHMRC Project Grants
BIOCHEMICAL DISSECTION OF P53 DEPENDENT APOPTOSIS PATHW
P53 依赖性细胞凋亡途径的生化剖析
  • 批准号:
    2885057
  • 财政年份:
    1999
  • 资助金额:
    $ 189万
  • 项目类别:
GENETIC AND BIOCHEMICAL EVENTS IN AB-INDUCED APOPTOSIS
AB 诱导的细胞凋亡中的遗传和生化事件
  • 批准号:
    2001588
  • 财政年份:
    1995
  • 资助金额:
    $ 189万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了